FDA ush­ers Mer­ck­'s star can­cer drug Keytru­da to­ward an­oth­er key check­point

Mer­ck counts 22 ap­proved in­di­ca­tions for Keytru­da across 14 dif­fer­ent can­cer types. It is now be­ing ush­ered to­ward one more.

The PD-1 block­buster has been grant­ed pri­or­i­ty re­view for an­oth­er set of blad­der can­cer pa­tients: those with high-risk non-mus­cle in­va­sive blad­der can­cer (NIM­BC) who haven’t un­der­gone cys­tec­tomies and are re­sis­tant to the stan­dard treat­ment. The bi­o­log­ics li­cense ap­pli­ca­tion will be dis­cussed at the FDA on­col­o­gy drug meet­ing on De­cem­ber 17, Mer­ck said, and has a PDU­FA date for next month, Jan­u­ary 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER